Nanotube bottoms are uniformly etched to produce consistent nanoscale pores.
Pressure from payers for improved adherence is driving the need to innovate novel solutions in drug delivery; with only 61.4% of patients actually taking their medication, non-adherence costs the United States, alone, more than $100B annually. In addition to the pain and compliance issues associated with injections and infusions, the delivery profile is often non-optimal, negatively affecting treatment outcomes. Oral delivery via pills does not have the pain associated with injections and infusions, yet still suffers from poor adherence. Extended release implants address all of these issues head on, and likely improve patient outcomes.
Nano Precision Medical is developing a biocompatible, miniaturized, subdermal implant with the NanoPortalTM membrane to provide long-term, substantially constant-rate delivery of therapeutic macromolecules for up to a year.
Poor adherence is a significant health issue and associated with increased hospitalization and mortality1
Adherence reduces healthcare resource use and decreases healthcare cost2
Even weekly dosing of GLP-1s has low adherence3,4
Simpler treatment regimens improve patient satisfaction5, adherence1, QoL and clinical outcomes1,5
Adherence significantly improves treatment goals of HbA1C reduction6,7 and weight loss5, and non-adherence can account for the difference in outcomes between RCTs and RWE6
Adherence to diabetes meds is low1,8 and is associated with inadequate glycemic control, higher medical costs and higher mortality9